IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

Steven R. Schuster, S Vincent Rajkumar, Angela Dispenzieri, William Morice, Alvaro Moreno Aspitia, Stephen Maxted Ansell, Robert Kyle, Joseph R Mikhael

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

IgM multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) are two distinct hematologic entities with the common finding of an IgM monoclonal gammopathy. Distinguishing these two diagnoses is critical as the approach to therapy is different. A priori, we defined IgM MM as a symptomatic clonal plasma cell proliferative disorder characterized by an IgM monoclonal protein (regardless of size), 10% or more plasma cells on bone marrow biopsy, plus the presence of lytic bone lesions and/or translocation t(11;14). Twenty-one patients met this definition of IgM MM. All 21 patients had lytic bone lesions. Of the 16 evaluated with FISH, 6 (38%) demonstrated t(11;14). Median overall survival was 30 months, which is similar to non-IgM myeloma patients treated during this period and shorter than what would be expected for WM. In this, the largest series of patients with IgM MM, we describe the clinical features and prognosis of patient with IgM MM using a strict definition for the disease. The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study.

Original languageEnglish (US)
Pages (from-to)853-855
Number of pages3
JournalAmerican Journal of Hematology
Volume85
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Waldenstrom Macroglobulinemia
Multiple Myeloma
Immunoglobulin M
Plasma Cells
Bone and Bones
Paraproteinemias
Bone Marrow
Biopsy
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

IgM multiple myeloma : Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. / Schuster, Steven R.; Rajkumar, S Vincent; Dispenzieri, Angela; Morice, William; Moreno Aspitia, Alvaro; Ansell, Stephen Maxted; Kyle, Robert; Mikhael, Joseph R.

In: American Journal of Hematology, Vol. 85, No. 11, 11.2010, p. 853-855.

Research output: Contribution to journalArticle

@article{7717890db35144a68aefc6afd9e2fcdb,
title = "IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia",
abstract = "IgM multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) are two distinct hematologic entities with the common finding of an IgM monoclonal gammopathy. Distinguishing these two diagnoses is critical as the approach to therapy is different. A priori, we defined IgM MM as a symptomatic clonal plasma cell proliferative disorder characterized by an IgM monoclonal protein (regardless of size), 10{\%} or more plasma cells on bone marrow biopsy, plus the presence of lytic bone lesions and/or translocation t(11;14). Twenty-one patients met this definition of IgM MM. All 21 patients had lytic bone lesions. Of the 16 evaluated with FISH, 6 (38{\%}) demonstrated t(11;14). Median overall survival was 30 months, which is similar to non-IgM myeloma patients treated during this period and shorter than what would be expected for WM. In this, the largest series of patients with IgM MM, we describe the clinical features and prognosis of patient with IgM MM using a strict definition for the disease. The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study.",
author = "Schuster, {Steven R.} and Rajkumar, {S Vincent} and Angela Dispenzieri and William Morice and {Moreno Aspitia}, Alvaro and Ansell, {Stephen Maxted} and Robert Kyle and Mikhael, {Joseph R}",
year = "2010",
month = "11",
doi = "10.1002/ajh.21845",
language = "English (US)",
volume = "85",
pages = "853--855",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - IgM multiple myeloma

T2 - Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia

AU - Schuster, Steven R.

AU - Rajkumar, S Vincent

AU - Dispenzieri, Angela

AU - Morice, William

AU - Moreno Aspitia, Alvaro

AU - Ansell, Stephen Maxted

AU - Kyle, Robert

AU - Mikhael, Joseph R

PY - 2010/11

Y1 - 2010/11

N2 - IgM multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) are two distinct hematologic entities with the common finding of an IgM monoclonal gammopathy. Distinguishing these two diagnoses is critical as the approach to therapy is different. A priori, we defined IgM MM as a symptomatic clonal plasma cell proliferative disorder characterized by an IgM monoclonal protein (regardless of size), 10% or more plasma cells on bone marrow biopsy, plus the presence of lytic bone lesions and/or translocation t(11;14). Twenty-one patients met this definition of IgM MM. All 21 patients had lytic bone lesions. Of the 16 evaluated with FISH, 6 (38%) demonstrated t(11;14). Median overall survival was 30 months, which is similar to non-IgM myeloma patients treated during this period and shorter than what would be expected for WM. In this, the largest series of patients with IgM MM, we describe the clinical features and prognosis of patient with IgM MM using a strict definition for the disease. The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study.

AB - IgM multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM) are two distinct hematologic entities with the common finding of an IgM monoclonal gammopathy. Distinguishing these two diagnoses is critical as the approach to therapy is different. A priori, we defined IgM MM as a symptomatic clonal plasma cell proliferative disorder characterized by an IgM monoclonal protein (regardless of size), 10% or more plasma cells on bone marrow biopsy, plus the presence of lytic bone lesions and/or translocation t(11;14). Twenty-one patients met this definition of IgM MM. All 21 patients had lytic bone lesions. Of the 16 evaluated with FISH, 6 (38%) demonstrated t(11;14). Median overall survival was 30 months, which is similar to non-IgM myeloma patients treated during this period and shorter than what would be expected for WM. In this, the largest series of patients with IgM MM, we describe the clinical features and prognosis of patient with IgM MM using a strict definition for the disease. The subset of patients without lytic lesions or t(11;14) but with immunophenotypic features suggestive of MM need further study.

UR - http://www.scopus.com/inward/record.url?scp=77957958192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957958192&partnerID=8YFLogxK

U2 - 10.1002/ajh.21845

DO - 10.1002/ajh.21845

M3 - Article

C2 - 20842638

AN - SCOPUS:77957958192

VL - 85

SP - 853

EP - 855

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -